The purpose of this study is to assess ondansetron for the treatment of methamphetamine dependence.

Condition	Treatment or Intervention	Phase
Amphetamine-Related Disorders	Drug: Ondansetron	Phase II

Further Study Details: 

Expected Total Enrollment:  154

This study was designed to be a preliminary assessment of the efficacy and safety of 3-wide range doses of ondansetron (0.25, 1.0 and 4.0 mg taken orally twice per day) to reduce methamphetamine use in subjects with methamphetamine dependence and to determine the optimal dose of ondansetron.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

18 years of age. Treatment seeking for meth dependence.

Exclusion Criteria:

Please contact site director for more details.

California
      Matrix Institute on Addictions, Costa Mesa,  California,  92627,  United States
      South Bay Treatment Center, Chula Vista,  California,  91911,  United States
Hawaii
      John A. Burns School of Medicine, Honolulu,  Hawaii,  96813,  United States
Iowa
      Powell Chemical Dependency Center, Des Moines,  Iowa,  50316,  United States
Missouri
      University of Missouri - Kansas City, Kansas City,  Missouri,  64108,  United States
Texas
      University of Texas Health Science Center, Houston,  Texas,  77225,  United States

Study chairs or principal investigators

Thomas Newton, M.D.,  Principal Investigator,  National Institute on Drug Abuse (NIDA)   

Study ID Numbers:  NIDA-CTO-0011-1
Record last reviewed:  November 2003
Last Updated:  November 18, 2004
Record first received:  June 18, 2002
ClinicalTrials.gov Identifier:  NCT00040053
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08